Pattern-recognition receptors such as Toll-like receptors (TLRs) are essential sensors implicated in the early and efficient innate immune response against pathogens. We have previously demonstrated that leukotriene B 4 (LTB 4 ) has the capacity to enhance leukocyte responses to TLR9 ligands and to control viral infection. In this report, we provide evidence that LTB 4 treatment of human neutrophils leads to a potentiation in proinflammatory cytokine secretion induced by various myeloid differentiation factor 88-dependent TLR agonists. LTB 4 failed to enhance TLR mRNA levels as well as expression of TLR2 and TLR4 receptors, suggesting that LTB 4 acts through intracellular mechanism(s) to potentiate neutrophil responses to TLR ligands. We found that while IRAK can be activated by LTB 4 , this process is dispensable to LTB 4 to potentiate neutrophil responses to TLR ligands since pretreatment of neutrophils with IRAK1/4 inhibitor did not affect its potentiating effects. However, our data clearly show that LTB 4 treatment of neutrophils led to the phosphorylation of downstream signaling molecules, TAK1 and p38, a process found essential to observe an increased secretion of cytokines by neutrophils activated with TLR ligands. Pretreatment of neutrophils with TAK1 or p38 kinase inhibitors strongly repressed the effect of LTB 4 on cytokine synthesis by neutrophils stimulated with LTA, LPS or CpG. The same pattern was observed in agonist-treated human embryonic kidney 293 cells transfected with TAK1-targeting siRNA where secretion of IL-8 was significantly reduced to basal levels. These results indicate that TAK1 and p38 kinases appear to be central in the 'priming effect' of LTB 4 on neutrophils to enhance response to TLR ligands.
Introduction
While tremendous progress is currently being made in our understanding of the innate response to microbial infections, interest in innate immune modulation as a therapeutic approach against infection is increasing (reviewed in refs 1, 2). Leukotriene B 4 (LTB 4 ) is a lipid mediator of inflammation derived from the cell membrane arachidonic acid. Since its discovery, the well-characterized functions of LTB 4 were predominantly associated with the recruitment and activation of neutrophils. However, complementary to its prominent role in inflammation, more evidence has linked LTB 4 to antiviral immunity (3) (4) (5) . We have showed that daily treatments with LTB 4 lead to a strong decrease in lung viral loads of mice infected with influenza A virus (IAV) compared with the placebo-treated groups (5) . We also observed that early viral clearance in lungs of infected mice was associated with the release of antimicrobial peptides mainly produced by lunginfiltrating neutrophils. Neutrophils appear to be important in the action of LTB 4 as IAV loads in lungs of neutrophil-depleted mice were not significantly reduced by LTB 4 . In addition, we have demonstrated that mice infected with murine cytomegalovirus (mCMV) and treated with LTB 4 have a lower viral burden than untreated control mice and that LTB 4 treatment can protect immunosuppressed mice from mCMV reactivation following allogenic transplantation (6) .
Activation of innate defense is essential for the control of microbial infections. Toll-like receptors (TLRs) are one of detector families responsible for sensing pathogens. In humans, 11 TLRs have been characterized and associated with the detection of different microorganisms and self-components. TLR2 and TLR4 are two members of the TLR family present on the cell membrane and are known to recognize various bacterial components. For optimal recognition of foreign antigens, TLR2 can form a heterodimer with either TLR1 or TLR6 (7, 8) and TLR4 can associate with CD14 or MD2 (9, reviewed in ref. 10) . Intracellular TLRs including TLR3, TLR7, TLR8 and TLR9 recognize nucleic acid structures from microorganisms or released from dying cells (reviewed in refs 11, 12) . The wide range of natural and synthetic ligands detected by TLRs makes those sensors an essential tool in the early detection and control of many microbial pathogens.
Recognition of microbial components by TLRs leads to the activation of intracellular signaling cascades resulting in production of several proinflammatory cytokines. Most TLR activation, with the exception of TLR3 and in certain conditions TLR4, involves the recruitment of the adaptor protein myeloid differentiation factor 88 (MyD88) to TLRs and subsequent complex formation with proteins such as IRAK1 and IRAK4 essential for downstream signaling (13) . Activated IRAK will then associate with TNFR-associated factor 6 which in turn will activate TAK1. Engagement of TAK1 will then result in activation of two important but distinct signaling pathways, one leading to the translocation of NF-κB, while the other pathway activates members of the MAPK family, such as p38, c-Jun kinase (JNK) and ERK 1/2 kinases leading to the activation of the transcription factor AP-1 (14, 15) . Translocation of these factors will thus culminate in the production of several proinflammatory cytokines.
The modulation of innate immunity through the triggering of TLR signaling cascades may thus represent an interesting approach to elicit protective responses against infections. In this regard, we recently demonstrated that LTB 4 has the capacity to modulate intracellular TLR9 expression in neutrophils and also to enhance secretion of inflammatory cytokines in response to TLR9 ligands (16) . In this report, we provide evidence that signaling induced by LTB 4 in human neutrophils intersects TAK1, a process leading to the potentiation in cytokine secretion. This strategy seems to prove beneficial for the host in the development of a proper inflammatory and antimicrobial response against pathogens.
Methods

Isolation of human neutrophils
Human neutrophils were obtained from peripheral blood of healthy medication-free volunteers after written informed consent in accordance with an internal review board-approved protocol at CHUQ Research Center (Centre Hospitalier de l'Université Laval). Briefly, peripheral blood leukocytes were enriched by dextran sedimentation, followed by centrifugation over a lymphocyte separation medium cushion at 1400 r.p.m. for 20 min. Neutrophils were obtained from the pellet as described (17) . Cell preparations were depleted of erythrocytes by osmotic shock, then washed and resuspended in RPMI-1640 supplemented with 10% fetal bovine serum (FBS) prior to use.
Cell treatments and ELISAs
Purified human neutrophils (5 × 10 6 cells) were pretreated or not pretreated with the appropriate kinase inhibitors of TAK1 (5Z-7-oxozeaenol) (Sigma-Aldrich, Oakville, Ontario, Canada), IRAK1/4 (benzimidazole) (Sigma-Aldrich), the p38 kinase (SB203580; pyridinyl imidazole) (Invivogen, San Diego, CA, USA) and with the JNK inhibitor (SP600125; pyrazolanthrone) (Cayman Chemical, Ann Arbor, MI, USA) for 30 min prior to stimulation. When indicated, neutrophils were pretreated with BLT1 antagonist U75302 (Cayman Chemical) for 60 min prior to stimulation. Neutrophils were stimulated with indicated concentrations of LTB 4 (Cayman Chemical), with LTA and the synthetic lipopeptide PAM 3 CSK 4 , two TLR2 agonists (Sigma-Aldrich), with poly I:C (dsRNA analog), a TLR3 agonist (Invivogen), with LPS, a TLR4 agonist (Sigma-Aldrich) and CpG-ODN 2216, a TLR9 agonist (Alpha DNA, Montreal, Québec, Canada) or with a combination of stimuli for 6 h or as mentioned otherwise. Cell incubation with different kinase inhibitors did not lead to significant cell death at the concentrations indicated, as determined by trypan blue dye assay. Following stimulation, cellular suspensions were centrifuged at 4°C and cell-free supernatants were collected and assayed for human TNFα (BioLegend, San Diego, CA, USA) or human IL-8 (Invitrogen Canada, Ontario, Canada) by ELISA following the manufacturer's instructions.
RT-PCR analysis
RNA extraction and RT-PCR analysis were performed as we previously described (16) . Briefly, human neutrophils (10 × 10 6 cells) were stimulated or not with LTB 4 (100 nM) for 2 h. Total RNA was extracted using Trizol reagent (Invitrogen) following the manufacturer's instructions and DNase-treated RNA (1 μg) was reverse-transcribed into cDNA using 40 units of RT Superscript II (Invitrogen). PCR detection of TLR1 (Invivogen, primer sequences, see catalog # rtp-htlr1) and TLR6 (Invivogen, primer sequences, see catalog # rtp-htlr6) was performed following the manufacturer's instructions. PCR for TLR2, TLR4 and GAPDH was performed using the following specific primers: TLR2, 5′-GGCCAGCAAATTACCTGTGTG-3′ (forward) and 5′-CCAGGTAGGTCTTGGTGTTCA-3′ (reverse); TLR4, 5′-CTGCAATGGATCAAGGACCA-3′ (forward) and 5′-TCCCACTCCAGGTAAGTGTT-3′ (reverse); and GAPDH, 5′-CCACCCATGGCAAATTCCATGGCA-3′
(forward) and 5′-TCTAGACGGCAGGTCAGGTCCACC-3′ (reverse). Amplified DNA was run on a 1% agarose gel containing ethidium bromide.
Flow cytometry analysis
Human neutrophils were stimulated or not with LTB 4 (100 nM) for indicated times. Following stimulation, neutrophils were washed twice in cold HBSS 1X. Cells were stained with an FITC-conjugated anti-human TLR2 (TL2.1) or with an FITC-conjugated anti-human TLR4 (HTA125) (Hycult Biotech, Uden, the Netherlands) diluted in HBSS 1X + 1% BSA. Cells were kept in the dark on ice for 30 min, and then washed twice in cold HBSS 1X. Fluorescence analyses were achieved using the BD FACSCanto II flow cytometer system (BD Bioscience, Ontario, Canada) on a total of 10 000 cells. ), LTB 4 (100 nM) or a combination of both stimuli. Following stimulation, cell-free supernatants were collected and assayed for human IL-8 detection.
Transfection assay
IRAK in vitro kinase assay
IRAK1 kinase assay was performed as described (18) . Human neutrophils (5 × 10 7 cells ml −1 ) were treated or not with IRAK1/4 inhibitor (100 μM) and stimulated with LTA (10 μg ml −1 ), LTB 4 (100 nM) or a combination of both stimuli. After 2 or 5 min, cells were lysed in cold lysis buffer (20 mM Tris pH 7.5, 1% Igepal, 1 mM EDTA, 150 mM NaCl, 10 mM β-glycerophosphate and protease inhibitor cocktail) (Roche Applied Science). Lysates were precleared overnight with protein A/G agarose beads (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and 1 μg of rabbit anti-rat IgG. Cleared lysates were immunoprecipitated with IRAK1 antibody (kindly supplied by Dr Shizuo Akira, Osaka University, Japan) or rabbit IgG (Sigma-Aldrich) and protein A/G agarose beads for 2 h at 40°C. Beads were washed three times with lysis buffer and followed by three washes with the kinase assay buffer (20 mM HEPES pH 7.5, 20 mM MgCl 2 , 3 mM MnCl 2 and 10 mM β-glycerophosphate). A quarter of the beads were kept for western blotting analysis for IRAK1 and the remaining beads were used for the IRAK1 kinase assay. Immunoprecipitates were incubated for 30 min at 37°C in kinase assay buffer (50 μl) containing 4 μg of MBP (Sigma-Aldrich), 4 μCi of g-P32 (GE Healthcare, Baie D'Urfé, Québec, Canada) and 5 μM of ATP (Sigma-Aldrich). The reaction was stopped by the addition of 20 μl of sample loading buffer (5× of 50 mM Tris-HCl pH 6.8, 10% glycerol, 2% SDS, 2.5% β-mercaptoethanol, 0.05% bromophenol blue). Samples were boiled and run on SDS-PAGE. Bands were detected using X-ray Kodak films (GE Healthcare) or by image analyzer (Bio-Rad, Mississauga, Ontario, Canada).
Western blot
Human neutrophils (5 × 10 6 cells) were stimulated with LTB 4 , LTA or a combination of stimuli at the indicated concentrations and for the indicated periods of time. Total proteins were extracted in lysis buffer (Cell Signaling Technology), prior to the addition of sample buffer (150 mM Tris pH 6.8, 1.2% SDS, 0.33% glycerol, 15% β-mercaptonethanol, 1% bromophenol blue) and boiled for 5 min. Samples were run on 10% SDS-PAGE. Proteins were transferred onto nitrocellulose or polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA) and blocked for 2 h with 5% BSA diluted in Triton Tris buffer at room temperature. Membranes were incubated overnight with anti-phospho-p38 (p-p38), anti-phospho-TAK1 (p-TAK1) or anti-p38 protein (Cell Signaling Technology) at 4°C. Incubation with HRP-conjugated secondary antibody was then performed for 1 h at room temperature and protein signals were visualized by enhanced chemiluminescence (Perkin Elmer, Waltham, MA, USA). Regarding p-TAK1, signals were visualized by LumiGLO Reserve chemiluminescent substrate kit (KPL, Gaithersburg, MD, USA).
Statistical analyses
Data were analyzed by one-tailed analysis of variance followed by Newman-Kheuls post hoc test using GraphPad PRISM version 3 for Windows (GraphPad Software, San Diego, CA, USA, www.graphpad.com). Differences were considered significant at *P ≤ 0.05.
Results
LTB 4 potentiates neutrophil responsiveness to TLR2 ligands
We have previously reported that LTB 4 has the capacity to increase production of inflammatory cytokines by leukocytes in response to CpG (16) . In this study, we wanted to compare the effect of LTB 4 treatment on neutrophil responses to various TLR stimuli and to determine the signaling events that contributes to LTB 4 effects. Firstly, neutrophils were stimulated with increasing concentrations of LTA alone or in combination with LTB 4 and IL-8 release was measured following a 6-h treatment. As shown in Fig. 1A , addition of LTB 4 to the cell cultures significantly enhances the production of IL-8 induced by LTA alone, suggesting that LTB 4 potentiates the response of neutrophils to TLR2 ligands. Neutrophils stimulated with LTB 4 alone secreted low levels of IL-8 (~300 pg ml −1 ) and its action on neutrophils was totally abrogated by pretreatment of cells with LTB 4 receptor antagonist U75302, supporting the conclusion that LTB 4 has a specific effect (Fig. 1A, inset) . We have repeated the same approach and determined the levels of TNFα produced. LTB 4 alone does not induce TNFα secretion by human neutrophils (16) . An increased secretion of TNFα in LTA-treated neutrophils should thus support the potentation effect of LTB 4 on neutrophils. As expected, we observed that LTB 4 increases the release of TNFα in LTA-treated neutrophils (Fig. 1B) supporting our assumption. Next, to further determine the optimal concentration of LTB 4 -mediated potentiation of neutrophils, cell cultures were stimulated with LTA in combination with increasing doses of LTB 4 . Neutrophils stimulated with the TLR2 ligand LTA secreted significant amounts of IL-8 (~4000 pg ml −1 ) (Fig. 1C) . When neutrophils were stimulated with both agonists, potentiation in IL-8 secretion was observed at a concentration as low as 1 nM of LTB 4 and increased in a dose-dependent manner reaching maximum secretion at LTB 4 concentrations ranging from 10 to 100 nM. The same secretion pattern was observed when TNFα secretion by human neutrophils was evaluated (Fig. 1D) . When neutrophils were in presence of both LTB 4 and LTA, a potentiation effect in TNFα secretion similar to what was observed with IL-8 was present in a dose-dependent manner, beginning at an LTB 4 concentration as low as 1 nM and reaching peak secretion in the range of 10-100 nM. This LTB 4 -mediated potentiation was statistically significant as early as 2 h post-stimulation with LTA for IL-8 secretion (Fig. 1E ) and 6 h for TNFα secretion LTB 4 potentiates TLR signaling 695 (Fig. 1F) and was sustained over time (tested up to 20 h of stimulation, data not shown).
LTB 4 enhances cytokine production by neutrophils stimulated with various TLR ligands
Next, we evaluated whether LTB 4 could enhance cytokine production by neutrophils to subsequent stimulation with various TLR agonists. We have thus compared the response of neutrophils with Pam 3 CSK 4 , an artificial lipopeptide recognized by TLR2, LPS, a TLR4 ligand, non-methylated CpG, a TLR9 agonist and poly I:C, a dsRNA analog recognized by TLR3. Potentiation of TLR2 signaling for enhanced IL-8 and TNFα production was observed when LTB 4 -primed neutrophils were stimulated with the synthetic TLR2 ligand PAM 3 CSK 4 ( Fig. 2A) . In fact, the addition of LTB 4 to neutrophil cultures stimulated with increasing concentrations of PAM 3 SCK 4 was found to enhance IL-8 secretion. Potentiation in IL-8 and TNFα secretion by LTB 4 was also specific since its effect was totally abolished by pretreatment of cell cultures with the antagonist U75302 (Fig. 2B and C) . We obtained similar results when neutrophils pretreated with LTB 4 were stimulated with LPS and ) alone or pretreated with LTB 4 for 30 min before stimulation with LTA for indicated times. Cell-free supernatants were harvested and tested for the presence of IL-8 (E) and TNFα (F). NS, not stimulated. *P ≤ 0.05 as compared with respective samples stimulated with LTA alone.
CpG. As observed in Fig. 2D and E, LTB 4 also potentiated IL-8 and TNFα secretion following stimulation with LPS as well as in response to CpG (Fig. 2F and G) . No effect was observed in neutrophils treated with poly I:C, which is consistent with the absence of TLR3 in this cell population (data not shown).
Together, these results demonstrate the capacity of LTB 4 to potentiate neutrophil responses to different TLR stimuli.
LTB 4 does not significantly alter TLR2 and TLR4 expression on neutrophils
We have previously reported that LTB 4 has the capacity to modulate TLR9 expression in human neutrophils and increase TLR9 ligand binding (16) . This prompted us to evaluate whether LTB 4 may also upregulate TLR2 and TLR4 expression on the neutrophil cell surface as well as expression of TLR1 and TLR6, which can form heterodimer complexes with TLR2. To test this assumption, neutrophils were stimulated for 2 h with LTB 4 and TLR mRNA levels were determined by RT-PCR. As shown in Fig. 3A , stimulation of neutrophils with LTB 4 did not increase mRNA levels of TLR1, 2, 4 and 6. Similarly, the levels of cell surface expression of TLR2 (Fig. 3B) and TLR4 (Fig. 3C) were not affected by LTB 4 treatment as determined by flow cytometry analysis. We also postulate that preincubation with LTB 4 followed by a stimulation with LTA should lead to a more elevated cytokine production by neutrophils than a simultaneous stimulation with both LTA and LTB 4 . Surprisingly, whether neutrophils were pretreated with LTB 4 prior to treatment with LTA or were stimulated simultaneously with a combination of LTB 4 and LTA, both treatments led to a similar enhanced IL-8 secretion by neutrophils (data not shown). This set of experiments therefore strongly suggests that the enhanced responsiveness of LTB 4 -treated neutrophils to TLR ligands is not related to an increased cell surface receptor expression, but could rather occur at a signaling level downstream of the receptor.
TAK1 contributes to potentiate the effect of LTB 4 on neutrophils
On the basis of the results obtained, we have postulated that LTB 4 potentiates neutrophil response by acting on intracellular event(s) downstream of TLR receptors. IRAK kinases and TAK1 kinase are signaling molecules of the MyD88-dependent pathway that subsequently lead to cytokine gene activation. Firstly, to determine whether IRAK contributes to the 'priming effect' of LTB 4 , neutrophils were pretreated with increasing doses of IRAK1/4 inhibitor prior to stimulation with the TLR2 ligands LTA alone, LTB 4 alone or with a combination of both agonists. As expected, we observed that IL-8 secretion induced by LTA was strongly reduced by treatment with IRAK1/4 inhibitor at a concentration as low as 10 μM (Fig. 4A) . Interestingly, pretreatment of neutrophils with this inhibitor had a marginal effect on LTB 4 -induced secretion of IL-8 at all concentrations tested (Fig. 4B) , suggesting that LTB 4 may act on downstream signaling events to compensate the shut off of IRAK1/4. Consistent with these data, the IRAK1/4 inhibitor did not block the potentiation of LTB 4 on IL-8 secretion in cells stimulated with both LTB 4 and LTA (Fig. 4C ). This set of experiments suggest that LTB 4 could preferentially modulate TLR2 signaling in neutrophils downstream of IRAK1/4.
Next, we pretreated neutrophils with increasing doses of TAK1 inhibitor and measured the IL-8 production following LTA and LTB 4 stimulation. Known activator of TAK1 following TLR2 engagement (19, 20) , effects of LTA on IL-8 production were also inhibited following treatment with TAK1 inhibitor (Fig. 4D) . Similarly, pretreatment of neutrophils with TAK1 inhibitor strongly abrogated IL-8 production induced by LTB 4 , reaching significant statistical inhibition at a concentration as low as 0.05 μM of inhibitor (Fig. 4E) . Furthermore, LTB 4 potentiation of IL-8 secretion in neutrophils stimulated with either LPS (TLR4 ligand), CpG (TLR9 ligand) or LTA was also strongly suppressed by pretreatment of cells with TAK1 inhibitor (Fig. 4F) . Again, these data provide evidence that TAK1 is a signaling molecule strongly implicated in LTB 4 action.
To further confirm the involvement of TAK1 in the potentiating effect of LTB 4 , HEK293 cells were transiently cotransfected with BLT1 (LTB 4 receptor) and TLR2 expression vectors (HEK cells do not constitutively express these receptors) and then transfected with IRAK1-and TAK1-targeting siRNA to suppress IRAK1 and TAK1 activation. Following transfection, cells were stimulated with LTA, LTB 4 or with both agonists and levels of IL-8 measured in supernatants from overnight cultures. As expected, IL-8 secretion induced by LTA was strongly inhibited by both siRNAs (Fig. 5) . However, ), (B and E) LTB 4 (100 nM) alone or (C and F) with a combination of LTB 4 (100 nM) and TLR agonists. Cell-free supernatants were assayed for IL-8 by ELISA. NS, not stimulated. *P ≤ 0.05 compared with indicated controls.
while the effect of LTB 4 alone was not significantly affected by IRAK1 siRNA, production of IL-8 in LTB 4 -stimulated HEK293 cells was strongly suppressed in cells transfected with TAK1 siRNA. Production of IL-8 was also significantly reduced in cells transfected with TAK1 siRNA and stimulated with both agonists, suggesting that TAK1 is central in the potentiation of TLR2 signaling mediated by LTB 4 .
P38 but not JNK is essential to LTB 4 effects
LTB 4 is recognized as an activator of MAP kinases p38 and JNK (21) (22) (23) , two MyD88-dependent signaling molecules downstream of TAK1 leading to cytokine gene activation upon TLR2 engagement in neutrophils (24) . We have thus evaluated the contribution of these kinases in both LTB 4 -treated neutrophils and in neutrophils treated with a combination of both stimuli. Following preincubation of cells with p38 kinase or JNK inhibitor, we observed that LTB 4 was fully dependent on p38 signaling, but not JNK signaling, for IL-8 secretion by neutrophils (Fig. 6A) . The same pattern was observed in neutrophils pretreated with the inhibitors and stimulated with a combination of LTB 4 and LTA (Fig. 6B) .
Activation of MyD88-dependent signaling molecules by LTB 4
While TAK1 and p38 appear to be central in LTB 4 -mediated potentiation of TLR signaling, we next wanted to investigate whether LTB 4 has the capacity to trigger IRAK1 kinase activity and the phosphorylation of downstream signaling molecules, namely TAK1 and p38. The next set of experiments was first designed to test whether LTB 4 can trigger IRAK1 kinase activity. To address this, we performed an in vitro IRAK1 kinase assay following neutrophil stimulation with LTA, LTB 4 or a combination of both stimuli. Some samples were also pretreated with IRAK1 inhibitor prior to cell activation as specificity controls. IRAK1 kinase activity was quantified by its ability to phosphorylate a substrate, MBP (18) . As presented in Fig. 7A , neutrophil stimulation by LTA led to IRAK1 kinase activity detectable at 2 and 5 min post-stimulation that was reduced by pretreatment with IRAK1 inhibitor. Surprisingly, LTB 4 alone also induced IRAK1 kinase activity by neutrophils as soon as 2 min after stimulation. Of great interest was the potentiated kinase activity present when neutrophils were stimulated with both LTA and LTB 4 . The combination of LTA and LTB 4 led to a strong as well as rapid and transitory response in IRAK1 kinase activity. These results demonstrate that LTB 4 has an intrinsic ability to activate IRAK1. Next we evaluated the phosphorylation status of TAK1 in neutrophils following stimulation with LTA, LTB 4 or with both stimuli. We observed that LTA stimulation alone led to TAK1 phosphorylation. This pattern of kinase phosphorylation shows a typical activation via TLR2 signaling (Fig. 7B) . Similarly, LTB 4 stimulation also led to phosphorylation of TAK1. When LTB 4 stimulation was performed in the presence of LTA, an upregulation in TAK1 phosphorylation was significantly visualized when compared with single stimulation with LTA. These results indicate that LTB 4 activates TAK1, an effect that can further be augmented in the presence of a TLR2 ligand.
To investigate whether IRAK is essential in the phosphorylation of TAK1 following LTB 4 stimulation, we pretreated neutrophils with IRAK1/4 inhibitor prior to treatment with LTB 4 and LTA, and determined the phosphorylation levels of downstream TAK1 and p38, the latter being activated via TAK1 (18) . LTA stimulation led to TAK1 and p38 kinase phosphorylation as already demonstrated (19, 20) . As expected, when neutrophils were pretreated with IRAK1/4 inhibitor followed by stimulation with LTA alone, TAK1 as well as p38 phosphorylation were reduced (Fig. 7C) . However, IRAK1/4 inhibitor did not significantly reduce TAK1 phosphorylation and had no effect on p38 phosphorylation levels following LTB 4 stimulation, suggesting once again that LTB 4 signaling can activate TAK1 and p38 kinases independently of IRAK1 activation. Stimulation with both LTA and LTB 4 led to enhanced TAK1 and p38 phosphorylation as previously observed. In the presence of IRAK1/4 inhibitor, phosphorylation levels for TAK1 were affected, which probably corresponds to the sole action of LTB 4 . Levels of p-p38 were not reduced when neutrophils were pretreated with IRAK1/4 inhibitor followed by stimulation with both stimuli.
To determine whether TAK1 and p38 are interconnected in LTB 4 -treated neutrophils, cells were pretreated with TAK1 inhibitor prior to LTB 4 treatment and phosphorylation levels of p38 were determined. Results show that levels of p-p38 were significantly reduced by the presence of TAK1 inhibitor (Fig. 7D) , suggesting that activation of p38 by LTB 4 is dependent on TAK1 to activate IL-8 secretion in neutrophils.
The results presented in this report suggest a mechanism describing how LTB 4 can potentiate the functional response of TLRs. This mechanism involves the TAK1 protein, a key signaling molecule of the MyD88 pathway. Figure 8 shows a schematic representation of the hypothetical LTB 4 -mediated innate immunity involving a MyD88-dependent signaling pathway. Stimulation with TLR ligands such as LTA, LPS and CpG results in IRAK1/4 activation which in turn induces TAK1 phosphorylation leading to the activation of the MAPK pathway and cytokine secretion. When LTB 4 is present, it may potentiate neutrophil response to TLR ligands by increasing levels of activation of IRAK1/4, TAK1 and p38 kinases, a process resulting in upregulation of cytokine gene activation. However, LTB 4 may also directly activate the TAK1-p38 axis to potentiate neutrophil response to TLR ligands. This mechanism might thus be activated in host cells triggered by LTB 4 in order to organize a strong innate response against invading pathogens.
Discussion
Neutrophils, key players of the innate immune system, do express different cell surface TLRs including TLR1, 2, 4, and 6 as well as the intracellular TLRs 7, 8, and 9 (25, 26) . We already reported that LTB 4 can positively modulate leukocyte responses to stimulation with CpG oligonucleotides, known ligands of intracellular TLR9 (16) . In this report, we have investigated the mechanism by which LTB 4 potentiates neutrophil response to various TLR ligands. Our results indicate that potentiation of cytokine release following stimulation with LTB 4 and TLR ligands does not correlate with expression levels of TLRs. In fact, contrary to TLR9 that was upregulated in LTB 4 -stimulated neutrophils, neither increased expression of cell surface TLR2, TLR4 nor the coreceptors TLR1 and TLR6 was observed on neutrophils following LTB 4 stimulation. TLR2 is known to recruit other coreceptor molecules such as TLR1 and TLR6 to form heterodimers for recognition of different agonist specificities (7, 8, 27) . CD14 and CD36 are other cell surface molecules linked to TLR2 for detecting microbial ligands (28, 29) . Regarding TLR4, cells need to coexpress TLR4 and CD14 or MD2 to mount a full response to LPS (9) . In contrast, TLR9 expression is sufficient on its own, probably in a homodimer form (30) , for proper signaling upon ligand binding. Therefore, it appears that control of TLR expression and signaling is regulated by different intracellular pathways and that TLR expression is modulated differently by LTB 4 whether the receptor is expressed at the cell surface or within the cell. The determination of which different cellular proteins are targeted by LTB 4 leading to recruitment of cell surface or intracellular TLRs awaits further investigation. Therefore, the action of LTB 4 on the TLR system of neutrophils seems to activate intracellular signaling to enhance cytokine production.
Our results provide compelling evidence that LTB 4 can in fact potentiate TLR-induced intracellular signaling leading to cytokine secretion by neutrophils. We have clearly demonstrated that LTB 4 can induce phosphorylation of TAK1 in neutrophils and moreover that enhanced secretion of cytokines induced by LTB 4 in LTA-stimulated neutrophils markedly involves the activation of TAK1, an effect strongly repressed by pretreatment of neutrophils with TAK1 inhibitor and also in HEK293 cells transfected with TAK1-targeting siRNAs. These results are thus in perfect agreement with our previous study showing that TAK1 is important for the LTB 4 -enhanced response of neutrophils to CpG stimulation (16) . Also of great interest are our results showing that LTB 4 can activate IRAK1 kinase in neutrophils, a central protein involved in TLR-mediated intracellular signaling. However, this effect on IRAK1 appears not to be crucial for LTB 4 to potentiate cytokine secretion in neutrophils stimulated with TLR ligands since pretreatment with IRAK inhibitor did not significantly affect LTB 4 action. We may thus postulate that IRAK1 is dispensable for the 'boosting effect' of LTB 4 on cytokine secretion, reinforcing the hypothesis that TAK1 is a key player for the LTB 4 -enhanced response of neutrophils to TLR ligands.
As expected, we also observed that p38 kinase participates in the potentiation of cytokine secretion by LTB 4 in LTA-treated neutrophils. Phosphorylation of p38 was induced by LTB 4 and enhanced by a combination of LTB 4 and LTA. However, p38 phosphorylation and the secretion of IL-8 were reduced by the pretreatment of neutrophils with TAK1 inhibitor, suggesting that TAK1 and p38 are interconnected in the action of LTB 4 . Therefore, it seems that LTB 4 prioritizes the ) or a combination of both agonists for 6 h. Cell-free supernatants were assayed for IL-8 by ELISA. NS, not stimulated. *P ≤ 0.05. TAK1-MAPK signaling axis to potentiate neutrophil response to TLR ligands. The formation of the IKK complex and translocation of NF-κB appear to be dispensable since they were not activated following LTB 4 treatment of neutrophils (data not shown). However, whether LTB 4 acts directly on TAK1-p38 or interferes with other kinases that subsequently will activate TAK1 remains to be investigated. Only few reports have specifically investigated direct intracellular kinase activation in neutrophils following binding of TLR ligands. Members of the MAP kinase family such as p38 kinase and JNK are known to lead to the activation of different transcription factors including AP-1 and NF-κB for secretion of proinflammatory cytokines following TLR engagement. On the other hand, LTB 4 is recognized as an activator of members of the MAP kinase family including ERK 1/2, p38 and JNK to induce different cellular activities (21) (22) (23) . Therefore, it is not surprising that LTB 4 and TLR signaling can be connected at many levels since common components are essential for their respective signaling cascades. With all evidence presented in this study and in our previous work (16), we propose that treatment of neutrophils with LTB 4 results in activation of TAK1 protein that subsequently will activate p38 kinase. Such effects of LTB 4 with a signaling component of the MyD88-dependent pathway will thus lead to an enhanced cytokine secretion in neutrophils following TLR engagement. While not essential, activation of IRAK1 (IRAK complexes) by LTB 4 may also potentiate enhanced secretion of cytokine induced by stimulation with TLR stimuli. The overall consequence of such cross talk between LTB 4 and MyD88-dependent pathway may thus favor an effective innate response against microorganisms known to be recognized by the TLR system. A previous study reported by Serezani et al. (31) has demonstrated that LTB 4 signaling via BLT1 receptor results in enhanced NF-κB activation and cytokine gene products in mouse macrophages. They also observed that the addition of exogenous LTB 4 upregulates TLR responsiveness of macrophages through a STAT-1-dependent MyD88 mechanism. Our study is thus consistent with these results, but highlights a new mechanism by which LTB 4 potentiates neutrophil responses to MyD88-dependent TLR ligands. Together, these studies suggest that LTB 4 signaling activity may vary from one cell population to another.
Since several innate receptors in the cell utilize common components to activate an effective immune response, it is not surprising that their signaling cascades are interconnected. In this regard, emerging evidence indicate that TLR signaling can also be connected with other intracellular sensors (reviewed in ref. 32 ). An interesting aspect of such cooperation is the cross talk between TLR and nucleotide-binding oligomerization domain (NOD) signaling pathways. In fact, NOD responses can be upregulated upon TLR stimulation (33, 34) , and interestingly, NOD2 was shown to interact with TAK1, a crucial molecule at the branch of IKK complex and MAPK activation in TLR signaling (35) . Such synergistic activity may thus contribute for optimal immune response against pathogens. In line with those studies, our report shows for the first time that LTB 4 can potentiate TLR signaling in human neutrophils via enhanced activation of TAK1 protein. More studies are thus needed for a better understanding of this signaling cross talk between LTB 4 and MyD88-dependent 4 activates phosphorylation of TAK1 protein (-), which subsequently leads to p38 phosphorylation. LTB 4 stimulation can also activate IRAK1, a process that seems dispensable (-) for LTB 4 effect on downstream signaling molecules. In the presence of TLR agonists, activation of TAK1 (and IRAK1) is potentiated by LTB 4 leading to enhanced signaling cascade downstream TAK1. In neutrophils, recognition of CpG by TLR9 seems to be independent of endosome formation and may imply involvement of other DNA sensors (16) . These mechanisms would consequently provide an enhanced immune defense of the host to counter pathogens. Black lines (-) represent TLR ligand signaling pathway. Bold red lines (-) represent potentiating effect of LTB 4 on TLR signaling.
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pathways and other pathways such as NOD2 to delineate the potential role of such immune mechanisms for enhanced defense against different classes of pathogens.
Funding
Canadian Institutes of Health Research (86449 to J.G.); Foundation Dr Georges Phénix to E.G. (BO506161).
